BioSpace News Archive

AstraZeneca has partnered with The National Fish and Wildlife Foundation (NFWF) to plant and sustain one million trees in the United States by the end of 2025.

BiondVax Pharmaceuticals Ltd. today announced the signing of definitive agreements with the Max Planck Society, the parent organization of the Max Planck Institute for Multidisciplinary Sciences (MPI), and the University Medical Center Göttingen (UMG), both in Germany, to enter into a strategic collaboration for the development of innovative nanosized antibodies (NanoAbs).

Taysha Gene Therapies, Inc. today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2021, and host a corporate update conference call and webcast on Thursday, March 31, 2022, at 8:00 AM Eastern Time.

Moderna today announced clinical and program updates demonstrating expansion and advancement of its mRNA pipeline.

Dante Labs announces the establishment of the first of its Medical Genomics Boards, strengthening the Company’s mission and research activity in this new frontier of healthcare, using genomics to promote prevention and treatment.

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), today announced it has received conditional approval from the Institutional Review Board (IRB) for its multi-site Phase 2b smoking cessation trial.

Stealth BioTherapeutics Corp announced today the upcoming presentation of new data at The Association for Research in Vision and Ophthalmology (2022) Annual Meeting.

InflaRx N.V., a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced financial and operating results for the year ended December 31, 2021.

Spectral Medical Inc. today announced its financial results for the fourth quarter and for the year ended December 31, 2021 and provided a corporate update.

CytoImmune Therapeutics, a clinical-stage immunotherapy company that is developing a novel class of engineered natural killer cell-based cancer therapies, announced the opening of the Company’s clinical cell manufacturing facility in Toa Baja, which was celebrated with a visit from the Governor of Puerto Rico, Pedro R. Pierluisi.